Rwanda: Draft Harm Reduction Guidelines Address Gaps for Drug Users

• Rwanda is developing draft national harm reduction guidelines to address critical healthcare gaps for people who use drugs.
• The guidelines propose enhanced access to HIV prevention, mental health support, and overdose response, including opioid agonist therapy and naloxone.
• Data highlights significant health disparities, with 11.2% HIV prevalence among people who inject drugs and 91% reporting shared needle use.
• Key principles include voluntary care, confidentiality, non-discrimination, and involving people who use drugs in service planning.
• The initiative aims to connect health facilities and community organizations, building on Rwanda's success in achieving 95-95-95 HIV targets.

Compliance officers and legal counsel for healthcare providers and NGOs in Rwanda should closely monitor the finalization and implementation of these draft national guidelines.

Rwanda is developing comprehensive `Rwanda draft harm reduction guidelines` aimed at addressing significant gaps in healthcare provision for `people who use drugs`. This strategic initiative seeks to enhance access to vital services, including `HIV prevention` and treatment, mental health support, and effective overdose response mechanisms. The overarching goal is to reach individuals who frequently encounter barriers to care, such as societal stigma and limited treatment options, ensuring they receive essential health services.

Evidence underscores the urgent need for these targeted interventions. Estimates cited in the draft guidance indicate an HIV prevalence of 11.2 percent among people who inject drugs. This figure stands in stark contrast to the 2.2 percent prevalence observed among adults aged 15 to 49 in the 2025 Demographic and Health Survey. While these statistics originate from distinct studies and populations, precluding direct comparison, they powerfully illustrate the pronounced health disparities faced by this vulnerable group. Furthermore, a 2024 mapping exercise identified 3,339 people who inject drugs across Rwanda, with 1,443 located in Kigali, highlighting a concentrated need for intervention.

The impetus for these `Rwanda draft harm reduction guidelines` is further reinforced by compelling data from recent studies. Research conducted in 2022 revealed that a staggering 91 percent of people who inject drugs had shared needles at least once, while 43 percent reported knowing someone who had succumbed to a suspected overdose. These findings underscore critical risks that the new guidelines aim to mitigate. The `Rwanda Biomedical Centre` (RBC) is spearheading this effort, building on the nation's notable success in its broader HIV response, having achieved the ambitious 95-95-95 targets by December 2024.

Dr. Zephanie Nzeyimana, the RBC's HIV Key Population Strategic Officer, has outlined foundational principles for the draft guidelines. These include a strong emphasis on voluntary and informed care, strict confidentiality, non-discrimination, and the active involvement of `people who use drugs` in the planning and delivery of services. Dr. Nzeyimana articulated that harm reduction is fundamentally about addressing the health risks individuals face and guaranteeing their access to prevention, treatment, and support without the impediment of stigma. She further noted that while Rwanda's progress in HIV prevention and treatment provides a robust foundation, it is imperative to extend these efforts to populations still exposed to preventable harm.

The proposed `Rwanda draft harm reduction guidelines` detail a range of critical interventions designed to improve `Rwanda healthcare` for `people who use drugs`. These include comprehensive `HIV testing and treatment`, care for sexually transmitted infections, services for viral hepatitis and tuberculosis, health education, provision of condoms, and robust overdose prevention strategies. A significant component of the new framework is the integration of `Rwanda opioid agonist therapy policy`.

Frederic Nsanzumuhire, acting director of the Substance Abuse Prevention and Management Unit within the RBC's Mental Health Division, presented clinical recommendations for opioid agonist therapy (OAT). The draft guidance specifically proposes the establishment of methadone services at selected sites, complemented by psychosocial support where feasible. Crucially, it also recommends widespread overdose education and improved `Rwanda naloxone access guidelines` at designated locations. The broader implementation strategy encompasses essential staff training, streamlined referral procedures, and the strengthening of linkages between community outreach programs and health facilities, ensuring a holistic and integrated approach to care.

The finalization and implementation of these `Rwanda draft harm reduction guidelines` represent a pivotal moment for public health in Rwanda, promising to significantly enhance `Rwanda drug user HIV prevention` efforts and overall well-being. By focusing on vulnerable populations, the guidelines aim to reduce health disparities and improve outcomes across the nation, building upon Rwanda's existing public health achievements, particularly in its HIV response. The initiative's emphasis on connecting health facilities with community organizations is expected to create a more accessible and less stigmatizing environment for `people who use drugs` seeking help.

Compliance officers and legal counsel for healthcare providers and NGOs in Rwanda should closely monitor the finalization and implementation of these draft national guidelines. It will be essential to ensure that institutional policies and practices are fully aligned with the new requirements concerning service delivery, patient rights—including confidentiality and non-discrimination—and reporting protocols related to harm reduction, HIV prevention, mental health, and opioid agonist therapy for `people who use drugs`. This proactive engagement will be crucial for effective integration and adherence to the forthcoming national standards.

Compliance officers and legal counsel for healthcare providers and NGOs in Rwanda should closely monitor the finalization and implementation of these draft national guidelines. They will need to ensure institutional policies and practices align with new requirements for service delivery, patient rights (confidentiality, non-discrimination), and reporting related to harm reduction, HIV prevention, mental health, and opioid agonist therapy for people who use drugs.

Source: Original reporting via source material.